FY2018 EPS Estimates for Johnson & Johnson (JNJ) Lowered by Jefferies Group
Johnson & Johnson (NYSE:JNJ) – Investment analysts at Jefferies Group lowered their FY2018 EPS estimates for shares of Johnson & Johnson in a research note issued on Wednesday. Jefferies Group analyst J. Holford now expects that the company will post earnings of $8.17 per share for the year, down from their prior forecast of $8.18. Jefferies Group currently has a “Buy” rating and a $160.00 target price on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $8.95 EPS, FY2020 earnings at $9.66 EPS and FY2021 earnings at $10.55 EPS.
JNJ has been the topic of a number of other research reports. Morgan Stanley upped their price target on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Cowen and Company reiterated an “outperform” rating and issued a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday. UBS AG reiterated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday, August 31st. BidaskClub lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $141.66.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/20/fy2018-eps-estimates-for-johnson-johnson-jnj-lowered-by-jefferies-group.html.
Johnson & Johnson (JNJ) traded up 0.25% during trading on Friday, reaching $142.40. The company’s stock had a trading volume of 5,634,488 shares. The firm has a 50 day moving average price of $133.48 and a 200-day moving average price of $130.63. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $143.62. The stock has a market cap of $382.20 billion, a price-to-earnings ratio of 24.77 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period in the previous year, the company posted $1.68 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
In related news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.19% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of JNJ. Harding Loevner LP acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. Lenox Wealth Advisors Inc. raised its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the period. IHT Wealth Management LLC raised its stake in Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $124,000. 65.90% of the stock is currently owned by institutional investors and hedge funds.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.